NuSil Technology, a cutting-edge manufacturer of silicone compounds for the healthcare, drug delivery and pharmaceutical industries, announced the launch of its MED-323 dimethicone product. The product reinforces NuSil's commitment to the pharmaceutical and cosmeceutical industries. (PRWeb Apr 24, 2008) Read
PTC Therapeutics initiates an international pivotal trial of PTC124 in patients with Duchenne/Becker muscular dystrophy (DMD/BMD) due to a nonsense mutation.
Micromet starts phase 1 clinical trial with its BiTE antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.
The expert panel, hosted by the Global Health Council, highlights the need for new solutions to reach goal of eradication. The topic of malaria eradication has gained traction recently due to the Gates Foundation's Call for New Global Commitment to
SACHEM announces the availability of a free displacement chromatography e-Learning program. With the growing popularity of SACHEM's Expell(TM), Isolis(TM) and Propell(TM) displacers, SACHEM is offering customers and scientists worldwide the ability to access information, learn about and explore displacement chromatography
Healthcare-associated infections are a staggering cause of increased provider costs and morbidity in the United States; and intravenous therapy complications are a major contributor to bloodstream infections. A new Mike Hurst-bylined article is now posted at the "Expert Information for
Simple product navigation on new Anachem website Anachem's new enhanced website has been dramatically re-developed to provide a faster and more effective tool that enables customers to find products they need at the click of a button. The highly advanced
FDA has granted final approval for Breckenridge Pharmaceutical's ANDA to market its generic version of Novo Nordisk's Activella Tablets (Estradiol/Norethindrone Acetate 1.0mg / 0.5mg) Tablets.
Elusys Therapeutics announced pivotal animal efficacy results of Anthim, a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.
Sysmex America announced the successful completion of Mercy Medical Center's (Canton, OH) beta studies for its integrated hematology and A1C automation solution.
VoicePort sponsors CBI's 7th Annual Forum on Patient Compliance, Adherence and Persistency in Philadelphia, PA, April 24-25. (PRWeb Apr 24, 2008) Read the full story at http://ww1.prweb.com/releases/2008/04/prweb873714.htm
Driven by the aging world population, and commensurate advancements in ophthalmic drug delivery techniques, the world ophthalmic pharmaceutical drugs market is projected to reach $12.86 billion by the year 2010. Rapid drug development, and the resulting spurt in new drug
This one-day event will be an essential platform to explore pricing policies, the needs of social systems, and the impact of low-cost Indian generics on European markets. (PRWeb Apr 23, 2008) Read the full story at http://ww1.prweb.com/releases/2008/04/prweb866024.htm
Metabasis Therapeutics has announced an extension to the sponsored research term under its collaboration with Merck & Co. for an additional year, through June 2009.
Allos Therapeutics has completed patient enrollment in Propel, the company's pivotal Phase II trial of PDX in patients with relapsed or refractory peripheral T-cell lymphoma.
Replidyne has discontinued enrollment in a placebo-controlled Phase III clinical trial testing faropenem medoxomil in patients with acute exacerbation of chronic bronchitis.
Lorus Therapeutics has started a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.
Argos Therapeutics has announced the closing of a $35.2 million tranched Series C financing. The financing was led by TVM Capital and included participation from new investors Mizuho Capital, Morningside Group and Japan Asia Investment.
